Therapeutic use of monoclonal anti-idiotype antibodies against B-cell lymphoma

  • A. Hekman
  • E. M. Rankin
  • R. Somers
  • W. ten Bokkel Huinink
Part of the Developments in Oncology book series (DION, volume 32)

Abstract

Human malignant B-cell tumors arise from a proliferation of a single clone of cells [1]. The immunoglobulin (Ig) which is expressed by the tumor cells is limited to the expression of one single VH and VL region, and to a single light chain. The unique variable region of the Ig, the idiotype, thus forms a specific tumor marker and a potential target for immunotherapy. Levy and colleagues [2] used a monoclonal anti-idiotype antibody to treat a patient with a nodular poorly-differentiated lymphocytic lymphoma, and achieved a complete remission which has lasted so far for 29 months. This group has treated seven more patients with anti-idiotype antibodies but no complete remissions have been obtained [3]. Polyclonal anti-idiotype antibodies raised in sheep have been given to one patient with promyelocytic leukemia [4] and to three patients with lymphoma [5]. There were transient reductions in the level of circulating lymphocytes, but no long-lasting antitumor effect was seen.

Keywords

Clay Migration Toxicity Albumin Lymphoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fialkow PJ, Klein E, Klein G and Singh S (1973). Immunoglobulin and glucose-6-phosphate dehydrogenase as markers of cellular origin in Burkitt lymphoma. J Exp Med 138: 89102.CrossRefGoogle Scholar
  2. 2.
    Miller RA, Maloney DG, Warnke T and Levy R (1982). Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306: 517–522.PubMedCrossRefGoogle Scholar
  3. 3.
    Lowder JN, Meeker TC, Maloney DG et al. (1984). Anti-idiotype monoclonal antibody therapy of human B-lymphocytic malignancy. Proc Amer Soc Clin Oncol 3: 250.Google Scholar
  4. 4.
    Hamblin TJ, Abdul-Ahad AK, Gordon J et al. (1980). Preliminary experience in treating lymphocytic leukaemia with antibody to immunoglobulin idiotypes on the cell surfaces. Brit J Cancer 42: 495–502.PubMedCrossRefGoogle Scholar
  5. 5.
    Macbeth FR, Stevenson FK, Stevenson GT and Whitehouse JMA (1983). Anti-idiotype antibody therapy of patients with non-Hodgkin’s lymphoma. Proceed 2nd Eur Conf Clin Oncol Cancer Nursing. Amsterdam, p. 75.Google Scholar
  6. 6.
    Smets LA, Taminiau J, Hahlen K et al. (1983). Cell kinetic responses in childhood acute non lymphocytic leukaemia during high-dose therapy with cytosine arabinoside. Blood 61: 79–84.PubMedGoogle Scholar
  7. 7.
    Mauer AM, Murphy SB, Hayes AB and Dahl GV (1977). Scheduling and recruitment in malignant cell populations. In: Drewinko B and Humphrey EM (Eds.). Growth Kinetics and Biochemical Regulation of Normal and Malignant Cells, pp. 855–864. Baltimore: Williams & Wilkins.Google Scholar
  8. 8.
    Miller RA, Maloney DG, McKillop J and Levy R (1981). In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukaemia. Blood 58:78–86.PubMedGoogle Scholar
  9. 9.
    Nadler LM, Stashenko P, Hardy R et al. (1980). Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 40: 3147–3154.PubMedGoogle Scholar
  10. 10.
    Cosimi AB, Burton RC, Colvin RB et al. (1981). Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32: 535–540.PubMedCrossRefGoogle Scholar
  11. 11.
    Miller RA, Oseroff AR, Stratte PT and Levy R (1983). Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62: 988–995.PubMedGoogle Scholar
  12. 12.
    Dillman RO, Shawler DL, Sobol RE et al. (1982). Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukaemia. Blood 59: 1036–1045.PubMedGoogle Scholar
  13. 13.
    Ball ED, Bernier GM, Cornwell GG et al. (1983). Monoclonal antibodies to myeloid differentiation antigens: In vivo studies of three patients with acute myelogenous leukaemia. Blood 62: 1203–1210.PubMedGoogle Scholar
  14. 14.
    Zimmerman TS, Godwin HA and Perry S (1968). Studies of leukocyte kinetics in chronic lymphocytic leukaemia. Blood 51: 277–191.Google Scholar
  15. 15.
    Stepslewski Z, Lubeck MD and Koprowski H (1983). Human macrophages armed with murine immunoglobulin G-2a antibodies to tumours destroy human cancer cells. Science 221: 865–867.CrossRefGoogle Scholar
  16. 16.
    Levy R and Miller RA (1983). Tumor therapy with monoclonal antibodies. Fed Proc 42 2650–2656.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1985

Authors and Affiliations

  • A. Hekman
    • 1
  • E. M. Rankin
    • 1
  • R. Somers
    • 1
  • W. ten Bokkel Huinink
    • 1
  1. 1.Netherlands Cancer InstituteAntoni van Leeuwenhoek HuisAmsterdamthe Netherlands

Personalised recommendations